Arvinas, Inc. (NASDAQ:ARVN) Shares Bought by Seven Eight Capital LP

Seven Eight Capital LP grew its stake in Arvinas, Inc. (NASDAQ:ARVN) by 576.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,239 shares of the company’s stock after purchasing an additional 33,434 shares during the period. Seven Eight Capital LP owned approximately 0.06% of Arvinas worth $1,045,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ARVN. Quest Partners LLC acquired a new position in Arvinas in the 2nd quarter valued at $42,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Arvinas during the first quarter worth about $44,000. Amalgamated Bank raised its holdings in Arvinas by 29.6% during the second quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock worth $59,000 after purchasing an additional 508 shares in the last quarter. Contravisory Investment Management Inc. acquired a new stake in Arvinas in the second quarter valued at about $185,000. Finally, Personal CFO Solutions LLC purchased a new stake in Arvinas in the 4th quarter valued at approximately $206,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on ARVN. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a report on Monday, September 9th. Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Arvinas in a research report on Tuesday, July 30th. Oppenheimer cut their price target on shares of Arvinas from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Wednesday, July 31st. Barclays decreased their price objective on shares of Arvinas from $60.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $87.00 target price on shares of Arvinas in a report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $57.50.

Arvinas Stock Up 0.1 %

NASDAQ ARVN opened at $25.63 on Friday. Arvinas, Inc. has a fifty-two week low of $13.57 and a fifty-two week high of $53.08. The business has a fifty day moving average of $26.31 and a 200-day moving average of $31.09. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -4.32 and a beta of 1.97.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, July 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($1.08) by $0.59. The firm had revenue of $76.50 million during the quarter, compared to analyst estimates of $33.27 million. During the same period in the previous year, the firm posted ($1.25) EPS. The company’s revenue for the quarter was up 40.4% compared to the same quarter last year. As a group, analysts anticipate that Arvinas, Inc. will post -3.51 EPS for the current year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.